Coming soon · Thursday 10 December · 17:00 CETRecording coming soon · Thursday 10 December · 17:00 CET
2026 Year in Review
Live Webinar2 CME credits · EACCME
2026 Year in Review
Continue With
Related Topics
Videos
Oct252026
ESMO 2026 SYMPOSIUM
SCLC
SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era
A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.
M. ReckS. PetersG. MountziosN. Reguart
Jul
20
2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies
Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi
Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.
O. Gautschi
May
04
2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies
Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro
Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.
A. Curioni-Fontecedro
Dec
18
2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs
2025 Approvals & Highlights
1 h 49 min
S. PetersC. RudinM. Reck
Sep
26
2025
ILCS 2025
SCLC
Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease
34 min
R. Manochakian
Sep
26
2025
ILCS 2025
Advanced NSCLC
Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond
32 min
A. Curioni-Fontecedro
Sep
26
2025
ILCS 2025
Immunotherapies
The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC
28 min
A. Filippi
Sep
26
2025
ILCS 2025
Immunotherapies
Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes
36 min
P. Forde
Sep
26
2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies
Latest Advances in Frontline EGFR+ NSCLC
14 min
A. Curioni-Fontecedro
Sep
26
2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies
Unlocking New Potentials in EGFR-Mutant NSCLC
30 min
A. Passaro
Sep
26
2025
ILCS 2025
ADCs
The ADC Revolution in Lung Cancer: New Targets, New Opportunities
27 min
N. Reguart
Sep
26
2025
ILCS 2025
Targeted Therapies
DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?
31 min
T. Newsom-DavisX. Le
Sep
26
2025
ILCS 2025
Targeted Therapies
Actionable Genomic Alterations – Including HER2 and MET
26 min
S. Saw
Sep
26
2025
ILCS 2025
Targeted Therapies
Targeting EGFR and ALK in NSCLC
26 min
T. John
Sep
26
2025
ILCS 2025
Advanced NSCLC
Open Discussion on Patient Cases
22 min
Jul
10
2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies
Targeted Therapies in NSCLC
1h 30 min
O. GautschiJ. NaidooN. Girard
Jun
25
2025
VIRTUAL ROUNDTABLE
Advanced NSCLCImmunotherapies
Immunotherapies in NSCLC
1h 47 min
P. FordeJ. RemonS. Peters
Jun
17
2025
VIRTUAL ROUNDTABLE
SCLCImmunotherapies
Small Cell Lung Cancer
1h 35 min
G. MountziosJ. SandsS. Peters
Oct
05
2024
INDUSTRY SYMPOSIUM
Advanced NSCLCADCs
Best Practices in Managing Adverse Events with ADCs in NSCLC
18 min
N. Girard
Oct
04
2024
ILCS 2024
Advanced NSCLCResectable NSCLC
Patient Cases & Open Questions
32 min
Articles
Oct
30
2026
RESEARCH
SCLCImmunotherapies
Tarlatamab gave an mOS of 13.6 months against 8.4 with chemotherapy in SCLC at extended DeLLphi-304 follow-up
C. RudinG. Mountzios
Oct
30
2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies
Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial
M. ReckN. GirardA. Filippi
Oct
29
2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies
Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2
T. CasconeP. Forde
Oct
29
2026
RESEARCH
Advanced NSCLCImmunotherapies
Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE
M. Pérol
Oct
27
2026
RESEARCH
SCLCImmunotherapies
Tarlatamab added to durvalumab maintenance extended OS in extensive-stage SCLC
J. SandsM. PérolA. Dingemans
Oct
26
2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies
Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC
Oct
23
2026
RESEARCH
SCLCImmunotherapies
KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC
J. SandsM. Reck
Oct
22
2026
RESEARCH
Advanced NSCLC
TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients
R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct
21
2026
SPONSORED
Advanced NSCLCImmunotherapies
The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC
A. Curioni-Fontecedro
Oct
21
2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC
ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational
U. Malapelle
Oct
19
2026
RESEARCH
Advanced NSCLCImmunotherapies
Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update
H. Horinouchi
Oct
18
2026
RESEARCH
Advanced NSCLCTargeted Therapies
First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg
X. LeD. PlanchardM. Pérol
Oct
16
2026
RESEARCH
Advanced NSCLCTargeted Therapies
Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months
A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct
16
2026
RESEARCH
Advanced NSCLC
Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study
L. Bubendorf
Oct
15
2026
NEWS
Resectable NSCLC
A papal diagnosis turns the world’s attention to its most diagnosed cancer
Oct
14
2026
RESEARCH
Advanced NSCLCTargeted Therapies
Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue
N. Girard
Oct
08
2026
RESEARCH
Advanced NSCLCTargeted Therapies
Amivantamab, lazertinib and bevacizumab gave a 33% response rate after osimertinib in AMAZE-lung
R. StahelM. PérolA. AddeoS. Peters
Oct
07
2026
RESEARCH
BiomarkersSCLC
IASLC pathologists propose a grade 3 category for lung carcinoids with more than 10 mitoses
P. Hofman
Oct
06
2026
RESEARCH
Advanced NSCLCImmunotherapies
Two-thirds of patients with PD-L1-high NSCLC received first-line immunotherapy alone in a real-world survey
D. Rodríguez-Abreu
Oct
05
2026
RESEARCH
Advanced NSCLCTargeted Therapies
A JCO review sets PACC mutations and exon 20 insertions apart from classical EGFR mutations in NSCLC
A. AddeoX. Le